Clinical Trial Update: Pharmacokinetic Study of MIN-101 in Healthy Subjects [Phase 1]

View source ↗

Summary

Minerva Neurosciences completed a Phase 1 pharmacokinetic study of MIN-101 in healthy subjects, outlining basic PK parameters.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MIN-101

Snippet

Sponsor: Minerva Neurosciences | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED